depression on semaglutide and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database depression from semaglutide The interplay

She listens to exactly what you need and makes my wrinkles disappear

72 AEs were reported in 23 (82%) participants with semaglutide and 14 AEs were reported in 7 (25%) participants with placebo

Obesity and overweight information (2022)

The three targets are GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors

doi: 10.2165/00007256-200434080-00003 68 Skrzypiec-SpringMRozmusJAbu FarajGMielczarekMSroczynskaPSroczynskiJet al

The treatment landscape for obesity and type 2 diabetes has been transformed by GLP-1 receptor agonists, offering substantial and sustained weight loss for patients around the globe